

SWIXX ENTERS INTO NEW DISTRIBUTION AGREEMENT WITH KRYSTAL BIOTECH FOR LATIN AMERICA

Baar, Switzerland, October 5, 2026 – Swixx BioPharma AG of Baar, Switzerland, announced today the expansion of its relationship with Krystal Biotech, Inc., with the signature of a new Distribution Agreement for Latin America. Under the Agreement, Swixx is appointed to exclusively distribute and commercialize VYJUVEK® (beremagene geperpavec-svdt) in 14 countries of Latin America, including the region's five largest pharmaceutical markets – Argentina, Brazil, Chile, Colombia and Mexico – as well as Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, Peru and Uruguay. The agreement expands upon the successful collaboration announced in September 2024, when [Swixx was appointed to commercialize VYJUVEK® across selected Central and Eastern European markets.](#)

VYJUVEK® is a herpes simplex virus type 1 (HSV-1) vector-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB)¹, a rare and severe genetic disease that affects the skin and mucosal tissues². DEB is caused by mutations in the COL7A1 gene, resulting in extremely fragile skin that blisters and tears from minor friction or trauma. VYJUVEK® is a non-invasive, topical, redosable gene therapy designed to deliver functional copies of the COL7A1 gene directly to DEB wounds.

 **Jean-Michel Lespinasse, Chief Executive Officer of Swixx Biopharma,** welcomed the expansion, **commenting:** “We are proud that Krystal Biotech continues to place its trust in Swixx and our teams. The expansion of our relationship reflects the value of our multi-regional platform and our ability to support innovative therapies through all stages of commercialization. The early traction we have achieved with VYJUVEK® in our initial markets is a strong testament to the capabilities, expertise and commitment of our teams in helping accelerate patient access to innovative treatments. We look forward to building on this momentum and helping ensure that patients across Latin America can benefit from this important therapy.”

 **Pascal Forget, Regional General Manager Latam, added:** “Our teams across Latin America are ready to support the successful introduction of VYJUVEK® throughout the region. By combining strong local expertise, established market access capabilities and close relationships with healthcare stakeholders, we are well positioned to help ensure that patients living with dystrophic epidermolysis bullosa gain timely access to this important treatment. We look forward to working closely with Krystal, healthcare professionals and patient communities across Latin America.”

Swixx BioPharma combines extensive regional coverage with deep local market expertise across its territories. Through established capabilities in market access, regulatory affairs, pharmacovigilance, medical affairs, patient support and commercial operations, Swixx supports biopharmaceutical partners in bringing innovative therapies to patients efficiently and compliantly. The new distribution agreement with Krystal Biotech reflects the confidence placed in Swixx's integrated commercialization platform and its ability to support patient access across multiple geographies.



About Swixx Group

Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With presence in more than 50 countries, 2,100 employees and sales which exceeded 1.4 billion Euros in 2025, the Group is one of the fastest-growing independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and CNS therapy area talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.



Swixx Group investor and partner inquiries:

Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com

Stuart Swanson, Head of Corporate Development
bd.info@swixxbiopharma.com

Swixx Group media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

References:

1. Food and Drug Administration, Package Insert. Available at: [Package Insert - VYJUVEK](#). Last accessed: July 2026. 2. Orphanet, Dystrophic epidermolysis bullosa. Available at: [Orphanet: Dystrophic epidermolysis bullosa](#). Last accessed: July 2026.

